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Summary Prostaglandins E2 and F2a (PGE2 and PGF2cx) were measured by gas liquid chromatography -
mass spectrometry (glc-inis) in extracts of primary tumours from 78 patients with early breast cancer. These
levels have been related to factors of established prognostic value and the patients disease-free interval.
Although there was a wide variation in amounts of both prostaglandins extracted from different tumours, no
significant relationship was observed between levels of prostaglandins and oestrogen receptors (ER), tumour
size, presence of lymph node involvement and disease-free interval following primary treatment. It therefore
seems unlikely that the level of these particular prostaglandins within breast carcinomas plays a fundamental
role in the prognosis of the disease.
Previous studies have shown that human mammary cancers
produce greater amounts of 'prostaglandin-like material'
than the normal tissues in which they arise (Bennett et al.,
1977; Bennett, 1982). It has been suggested that increased
prostaglandin levels might be related to tumour growth and
to the dissemination of the disease (Bennett et al., 1977;
Rolland et al., 1980).
However, investigations into the possible prognostic
significance of prostaglandins in breast cancers are not
consistent. It has been reported that tumour prostaglandin
levels are elevated in patients with a poor prognosis (Bennett
et al., 1977). Conversely, it has also been suggested that
increased prostaglandin levels are associated with favourable
prognostic indices (Karmali et al., 1983; Fulton et al., 1982;
and Campbell et al., 1982). A further study (Wilson et al.,
1980) found no relationship between prostaglandin levels and
established prognostic factors.
The reason for such disparity is not completely clear but
differences in the methodology used to quantitate
prostaglandins may be one important factor. Most
investigations have employed bioassay or radioimmunoassay
which do not necessarily identify individual prostaglandins.
The aim of the present study, therefore, was to measure
PGE2 and PGF2a levels in primary breast cancer using the
more definitive technique of glc-ms and to correlate these
prostaglandin levels with factors of established prognostic
value.
Materials and methods
Tumour was obtained from 78 women with early carcinoma
of the breast i.e. with no evidence of metastatic disease at
the time of presentation. These patients comprised 12
premenopausal, 9 perimenopausal (within 5 years of the last
menstrual period) and 57 postmenopausal women. Tumour
material, removed at mastectomy or biopsy from the
primary cancer, was kept at 0°C and immediately transferred
to the laboratory. Following removal of tissue for histo-
pathological diagnosis, the remaining material was dissected
free of extraneous fat and divided for assays of prosta-
glandins and steroid receptors.
Measurement ofprostaglandins
Formation ofderivatives Tumour samples were weighed and
homogenized in ethanol as previously described (Watson et
al., 1984). Internal standards (20-ethyl PGF2ot and 20-methyl
PGE2) were added and the samples derivatized by oximation
and methylation. Further derivatization to the t-butyldi-
methylsilyl ether was then performed and the resultant
sample purified by passage through a Sephadex LH-20
column and analysed by glc-ms.
Gas chromatography - mass spectrometry Samples were
analyzed with an Erba Science gas chromatograph coupled
through an all-glass jet separator to a V.G. 305 spectrometer
as previously described (Watson et al., 1984). For analysis of
PGF2x the mass used was m/z 653 and 681 and for PGE2,
m/z 666 and 680. The ions measured were the M-57 ions
resulting from the loss of a t-butyl radical from the
molecular ion. Quantitation was achieved by comparing the
areas of the sample peak with those of the corresponding
standards. Procedural losses (2040%) were corrected by
monitoring the recovery of the internal standards. For intra-
assay precision the coefficient of variation was 13%, (n=34);
and values for interassay precision were 18 and 21% (n=9)
for PGF2a and PGE2 respectively
Oestrogen receptors
Level of oestrogen receptors was determined by saturation
analysis (Hawkins et al., 1975). Tumour cytosol was
incubated overnight at 4"C with (2,4, 6, 7) [3H] 171i-
oestradiol (100 Ci mmol- 1). Free and bound steroid were
separated by addition of dextran-coated charcoal. Following
centrifugation the bound fraction (in the supernatant) was
measured by liquid scintillation counting. Quantitation of
receptors was determined by Scatchard analysis (Scatchard,
1949). Values in excess of 5fmolmg-' cytosol protein were
designated receptor positive.
Statistical analysis
As the distribution of values for both PGF2a and PGE2 was
skewed, non-parametric tests (i.e. Wilcoxon's rank test and
Spearman's rank correlation) were used throughout.
Statistical differences are given by P values as indicated in
the text except for those not reaching significance (P>0.05).
Results
The range of values for PGE2 and PGF2 c was respectively, 6
to 977ngg-' tissue (median 75) and 2 to 817ngg-I tissue
(median 56) in the 78 tumours (Figure 1). There was a
highly significant correlation between amounts of PGE2 and
PGF2a (P<0.001) as previously reported (Watson et al.,
1984).
In order to determine if tumour levels of PGE2 and PGF2
relate to prognosis in patients with early disease, the
prostaglandins were examined in relation to oestrogen
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Figure 1 Levels of PGE2 and PGF2 x in 78 primary breast
cancers. Lines represent the median values.
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receptor status, lymph node involvement, tumour T stage
(assessed according to UICC TNM classification) and
disease-free interval.
Oestrogen receptors were present in 60 of the 78 tumours
(77%). The median value of both PGE2 and PGF2 x was
higher in tumours with oestrogen receptors but the difference
was not significant from the receptor-negative subgroup
(Figure 2). Of 77 patients in whom lymph nodes were
biopsied 54 patients (70%) had histologically involved nodes.
There was, however, no significant difference in either
tumour PGE2 or PGF2 levels between the lymph node
positive and negative groups (Figure 3). The number of
patients staged as T1 to T4 was respectively 6, 49, 11 and 12.
There was no significant difference in levels between these
groups (Figure 4), although the median value tended to
increase with advancing stage.
In 44 patients at least 30 months had elapsed since their
initial biopsy or mastectomy. During this period 14 patients
presented with recurrent disease while the remaining 30
appeared disease-free. There was, however, no significant
Figure 3 Levels of prostaglandins in 54 lymph node positive
(+ve) and 23 negative (-ve) tumours. Lines represent median
values. No significant difference between the groups by Wilcoxon
rank test.
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Figure 4 Levels of prostaglandins grouped according to T stage
(T1-T4). Lines represent median values. No significant
difference between individual groups by Wilcoxon rank test or
trend between the groups by Spearman's rank correlation.
difference in either PGE2 or PGF2a levels between these two
subgroups of patients (Figure 5).
No significant difference in prostaglandin levels was
detected between tumours which developed subsequent
recurrences at different sites (i.e. local, bone or visceral), but
numbers are too small for meaningful analysis (Table I).
Discussion
-ve
Figure 2 Levels of prostaglandins in 60 oestrogen-receptor-
positive (+ve) and 18 negative (-ve) tumours. Lines represent
median values. No significant difference between the groups by
Wilcoxon rank test.
Considerable attention has been given to the possible role of
prostaglandins in the natural history of breast cancer, largely
as a result of reports that breast tumours may contain
elevated amounts of prostaglandin-like material (Bennett et
al., 1977). Since prostaglandins possess both osteolytic (Klein
& Raisz, 1970) and haemodynamic properties (Moncada &
Vane, 1980), local production of prostaglandins by tumour
cells might aid subsequent spread.
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Fiu 5 Levels of prostaglandins in tumours which did not
recur within 30 months of initial treatment (NR) and in tumours
which recurred within this time (R). Lines 'represent median
results. No significant difference between the groups by
Wilcoxon rank test.
Table I Tumour prostaglandin concentration and site of recurrent
disease
.4mount (ngg ' tissue)
PGE2 PGF2z
Site ofRecurrence Number Range (median) Range (median)
Local 6 14-104 (53) 36-174 (42)
Bone 1 319 144
Visceral 4 35-258 (62) 43- 67 (65)
Multiple sites 3 32-137 (77) 43- 89 (74)
Initial results from one group (Bennett et al.. 1977). using
bioassay techniques to measure prostaglandins. provided
confirmatory evidence for this theory. patients with tumours
possessing high basal or synthesized levels of prostaglandins
being more likely to present with skeletal metastases and
having shorter post-surgery survival times (Bennett et al..
1979). However. more recent results from other workers
have been conflicting and have not necessarily found that
elevated tumour prostaglandins are related to poor
prognosis.
Thus. studies of prostaglandin synthesis in microsomal
preparations of breast cancers showed an increased
production both in tumours with a poor prognosis on
account of nodal involvement or the absence of steroid
receptors. and in those with a better prognosis due to a low
T-stage (Rolland et al.. 1980).
Furthermore. there are studies in which high prostaglandin
levels are consistently associated with good prognostic
factors. For example. Vergote et al. (1985) found higher
PGF,i levels in tumours with steroid receptors and in those
from women without nodal metastases. Whilst this positive
correlation with steroid receptors has been confirmed by
Campbell et al. (1981). Fulton et al. (1982). Karmali et al.
(1983) and Watson and Chuah (1985). others (Wilson et al..
1980: Watson et al.. 1984) found no significant difference in
prostaglandin levels between oestrogen receptor positive and
negative tumours. There are. therefore, wide discrepancies in
reports from different groups which could be attributable to
several vanrable factors.
For example, Bennett's studies (1977). are on tissues from
several London hospitals. This would be expected to
exacerbate variability associated with the time interval
between biopsy and extraction and there may be differences
in the degree of tissue trauma and operational procedures
which might affect the levels of prostaglandins. Enzymes
associated with prostaglandin synthesis are particularly labile
(Egan et al.. 1978) and it is essential to minimise delay and
trauma in tissue processing. Pathological assessment and
clinical staging can also vary between centres and so may
introduce further inconsistencies.
Previous studies have also used a variety of methods by
which to measure prostaglandins and many have employed
bioassay or radioimmunoassay techniques, which do not
positively identify individual prostaglandins. Bioassay
measures only 'prostaglandin-like material', and the accuracy
of radioimmunoassay depends on the specificity of
antibodies used. Furthermore, different preparations of
tumour tissue have been used for prostaglandin estimation.
Some workers have employed microsomal preparations
(Rolland et al.. 1980). Others have used crude tumour
homogenates (Bennet et al., 1977), either extracting directly
with ethanol to measure 'basal' levels or indirectly from an
aqueous solution after incubation with endogenous precursor
or added arachidonic acid to determine 'synthesized' levels.
Against this confused background, it is clear that the
addition of a further uncontrolled study is unlikely to swing
the balance decisively in favour of prostaglandins being
either a poor or favourable prognostic sign. It is, therefore.
worth emphasizing the characteristics of the present study
which commend it.
Firstly. all the tumours are derived from patients attending
a single breast unit. This means that (a) all patients were
staged. treated and followed-up according to strict and
uniform protocols; (b) all the tumours were routinely
collected from the same operating theatre and were subject
to similar transport procedures. The problem of variations in
handling time due to the constraints of clinical and
pathological demands have thus been minimised although
not eliminated: (c) prostaglandins have been measured by
glc-ms. the most definitive method of identification presently
available. We elected to measure 'basal' levels of prosta-
glandins for the reasons previously explained (Watson et al..
1984).
Using these methods. levels of tumour PGE, and PGF,x
were not significantly related to tumour oestrogen receptor
status. lymph node involvement. tumour size, or. in a subset
of patients. disease-free interval. This study, therefore.
provides no definitive evidence that prostaglandins are
related to already established prognostic factors. The absence
of a correlation with early tumour recurrence would also
appear to exclude a role for the prostaglandins as an
independent prognostic parameter. Our study does not
exclude the possibility that prostaglandins are involved in the
later stages of the natural history of the disease. but this can
be determined only by extended patient follow-up.
Measurements in the present study have also been
confined to PGE, and PGF, o but many physiological and
pathological effects formerly associated with classical prosta-
glandins may be attributable to the action of other
oxygenated metabolites of arachidonic acid. It may.
therefore. be pertinent that in a recent study (Karmali et al..
1983) thromboxane B2 was the only arachidonate metabolite
to show a significant relationship with tumour size. positive
lymph nodes and distant metastases.
In conclusion, while greater efforts can be made to
control the numerous non-specific variables involved in the
measurement of prostaglandin levels in breast tumours. it is
doubtful whether such studies on classical prostaglandins.
PGE2 and PGF2:x, are likely to provide useful information
on the dissemination and natural history of breast cancer.
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